3/4/2014 8:27:19 AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company’s lead antibiotic candidate, eravacycline, is currently in Phase 3 development for use as a potential first-line monotherapy for the treatment of multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by